Frequent DNA methylation of MiR-129-2 and its potential clinical implication in hepatocellular carcinoma
Version of Record online: 12 APR 2013
Copyright © 2013 Wiley Periodicals, Inc.
Genes, Chromosomes and Cancer
Volume 52, Issue 7, pages 636–643, July 2013
How to Cite
Lu, C.-Y., Lin, K.-Y., Tien, M.-T., Wu, C.-T., Uen, Y.-H. and Tseng, T.-L. (2013), Frequent DNA methylation of MiR-129-2 and its potential clinical implication in hepatocellular carcinoma. Genes Chromosom. Cancer, 52: 636–643. doi: 10.1002/gcc.22059
- Issue online: 15 MAY 2013
- Version of Record online: 12 APR 2013
- Manuscript Accepted: 5 MAR 2013
- Manuscript Received: 15 NOV 2012
- Technology Development Program from Ministry of Economic Affairs, Republic of China. Grant Number: 101-EC-17-A-04-04-0528
Hepatocellular carcinoma (HCC) is a highly malignant tumor with poor prognosis and high mortality due to a lack of effective medical treatment and apparent early stage symptoms. Understanding molecular mechanism of cancer development is crucial for HCC diagnosis, prognosis, and treatment. Recently, microRNAs have been shown to play an important role in carcinogenesis, being regulated by DNA methylation in several cases. In this study, a whole genome approach was used to identify methylation-regulated miRNAs in HCC, finally focusing on miR-129-2. MiR-129-2 methylation and reduced expression were observed in all examined HCC cell lines but not in normal liver cells and tissues. In 39 (93%) of 42 HCC, the methylation levels of miR-129-2 were significantly increased in tumor tissues compared with adjacent normal tissues. Furthermore, miR-129-2 methylation was detectable in plasma samples from HCC patients, but not in plasma samples from healthy individuals or patients with liver cirrhosis. At a cut-off value of −2.36 (log2 transformation of methylation level), it was possible to distinguish HCC from healthy and cirrhotic controls with sensitivity and specificity of 88% and 100%, respectively. This study indicates that miR-129-2 methylation is highly accurate in distinguishing HCC patients from cirrhosis patients and healthy individuals, implying its potential utility as an early diagnostic marker for HCC. © 2013 Wiley Periodicals, Inc.